Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 18/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404702 | 0.79 | GPR35 (1.00) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL1030730 | 0.78 | GPR35 (0.70) | GPR35 | |
| SCHEMBL10186088 | 0.74 | GPR35 (0.66) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL2176207 | 0.71 | GPR35 (0.61) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL10186093 | 0.70 | GPR35 (0.60) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL15342922 | 0.69 | GPR35 (0.67) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL27581548 | 0.68 | AXL (0.43) | GPR35PKMNPSR1 | |
| SCHEMBL10144278 | 0.65 | GPR35 (0.73) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL27857061 | 0.65 | GPR35 (0.49) | GPR35PKM | |
| SCHEMBL406991 | 0.64 | GPR35 (0.62) | GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| WO-2011081971-A2 | EGFR/VEGFR DUAL MODULATORS AND METHODS OF USING | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | GPR35 1127/4885PKM 4079/4885NPSR1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.